Professor
Institute of Translational Medicine
The First Affiliated Hospital
School of Medicine, Zhejiang University
Hangzhou 310058, China
Biography
Dr. Junxia Min currently serves as a professor at Institute of Translational Medicine & The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. In aging research area, Dr. Min has been co-leading the world largest centenarian cohort “The Chinese Longitudinal Healthy Longevity Study (CLHLS)”. Based on this 19-year followed cohort study, the team has uncovered key genetic factors that associated with longevity.
Dr. Min earned her Ph.D. from University of Missouri-Columbia in the United States in 2006. The key finding during her PhD training was discovered the important roles of sphingolipid metabolic pathway in cancer treatment. From 2006-2010, Dr. Min had her postdoctoral training at the Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School. She identified the important novel epigenetic regulatory mechanismsintumorigenesis. Since 2010, Dr. Min joined Novartis Department of Oncology as a group leader at Boston, U.S.A., where her group discovered and functionally validated several novel targets for further clinical drug development.
Prof. Min’s laboratory is mainly focused on 3 areas:
1. to identify novel cancer therapeutics; 2. to design effective interventions for improving healthspan for aging populations.
